MedTrace Logo

Clinical Trial to Assess the Importance of Nephrectomy

NCT00930033 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 452

Last updated 2025-09-05

No results posted yet for this study

Summary

The study compare the standard treatment with nephrectomy + sunitinib to treatment with sunitinib alone without nephrectomy. This study will be the first trial on this competitive context

Conditions

  • Metastatic Renal Cell Carcinoma

Interventions

PROCEDURE

Nephrectomy

Current surgery

OTHER

Sunitinib alone

Sunitinib alone without nephrectomy

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • URC-CIC Paris Descartes Necker Cochin

    collaborator OTHER

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Arnaud Mejean, MD PhD · Assistance Publique - Hôpitaux de Paris

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-09
Primary Completion
2018-10-22
Completion
2018-10-22

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00930033 on ClinicalTrials.gov